https://www.selleckchem.com/products/ldk378.html
EPTB patients with limited disease. The QFT® Plus test does not appear to be a suitable marker for therapy monitoring. should be examined in EPTB patients even in case of normal diagnostic imaging of the chest.New oral anticoagulants (NOACs) is the preferred treatment in secondary prophylaxis of venous thromboembolic events (VTE). The aim of this study was to investigate possible risk factors associated with major bleeding in VTE-patients treated with NOACs. In this retrospective register-based study we screened the Swedish anticoagulati
إعجاب
علق
شارك
